Home › PTC Therapeutics Begins Rolling NDA Submission To The FDA For Translarna To Treat Duchenne Muscular Dystrophy
 

Keywords :   


PTC Therapeutics Begins Rolling NDA Submission To The FDA For Translarna To Treat Duchenne Muscular Dystrophy

2014-12-29 01:59:52| drugdiscoveryonline Home Page

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD)

Tags: treat begins rolling submission

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
05.11Shoppers warned over luxury advent calendar scams
05.11Durable Floor Coating from HMG Paints Transforms FC United\'s SMRE Bar
05.11Teknos Poland Honored by Farby i Lakiery
05.11Xumo teams up with Target to offer Hisense Xumo TVs
05.11KT launches 8K AI-powered IPTV set-top box
05.11Tropical Storm Rafael Graphics
More »